184 related articles for article (PubMed ID: 14991580)
1. Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice.
Kitamura T; Itoh M; Noda T; Matsuura M; Wakabayashi K
Int J Cancer; 2004 Apr; 109(4):576-80. PubMed ID: 14991580
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis.
Kitamura T; Kawamori T; Uchiya N; Itoh M; Noda T; Matsuura M; Sugimura T; Wakabayashi K
Carcinogenesis; 2002 Sep; 23(9):1463-6. PubMed ID: 12189188
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor.
Oshima M; Murai N; Kargman S; Arguello M; Luk P; Kwong E; Taketo MM; Evans JF
Cancer Res; 2001 Feb; 61(4):1733-40. PubMed ID: 11245490
[TBL] [Abstract][Full Text] [Related]
4. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
[TBL] [Abstract][Full Text] [Related]
5. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice.
Nakatsugi S; Fukutake M; Takahashi M; Fukuda K; Isoi T; Taniguchi Y; Sugimura T; Wakabayashi K
Jpn J Cancer Res; 1997 Dec; 88(12):1117-20. PubMed ID: 9473726
[TBL] [Abstract][Full Text] [Related]
6. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
Jacoby RF; Cole CE; Tutsch K; Newton MA; Kelloff G; Hawk ET; Lubet RA
Cancer Res; 2000 Apr; 60(7):1864-70. PubMed ID: 10766173
[TBL] [Abstract][Full Text] [Related]
7. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice.
Chulada PC; Thompson MB; Mahler JF; Doyle CM; Gaul BW; Lee C; Tiano HF; Morham SG; Smithies O; Langenbach R
Cancer Res; 2000 Sep; 60(17):4705-8. PubMed ID: 10987272
[TBL] [Abstract][Full Text] [Related]
8. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
9. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice.
Zeytin HE; Patel AC; Rogers CJ; Canter D; Hursting SD; Schlom J; Greiner JW
Cancer Res; 2004 May; 64(10):3668-78. PubMed ID: 15150127
[TBL] [Abstract][Full Text] [Related]
10. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2).
Oshima M; Dinchuk JE; Kargman SL; Oshima H; Hancock B; Kwong E; Trzaskos JM; Evans JF; Taketo MM
Cell; 1996 Nov; 87(5):803-9. PubMed ID: 8945508
[TBL] [Abstract][Full Text] [Related]
11. Reduction of intestinal neoplasia with adenomatous polyposis coli gene replacement and COX-2 inhibition is additive.
Lew JI; Guo Y; Kim RK; Vargish L; Michelassi F; Arenas RB
J Gastrointest Surg; 2002; 6(4):563-8. PubMed ID: 12127122
[TBL] [Abstract][Full Text] [Related]
12. Combined effects of prostaglandin E receptor subtype EP1 and subtype EP4 antagonists on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice.
Kitamura T; Itoh M; Noda T; Tani K; Kobayashi M; Maruyama T; Kobayashi K; Ohuchida S; Sugimura T; Wakabayashi K
Cancer Sci; 2003 Jul; 94(7):618-21. PubMed ID: 12841871
[TBL] [Abstract][Full Text] [Related]
13. Chemoprevention of intestinal polyposis by COX-2 inhibition: from mouse to man.
Bresalier RS
Gastroenterology; 2002 Jan; 122(1):234-6. PubMed ID: 11781300
[No Abstract] [Full Text] [Related]
14. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
15. A cyclooxygenase-2 inhibitor, nimesulide, inhibits postinitiation phase of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters.
Furukawa F; Nishikawa A; Lee IS; Kanki K; Umemura T; Okazaki K; Kawamori T; Wakabayashi K; Hirose M
Int J Cancer; 2003 Apr; 104(3):269-73. PubMed ID: 12569549
[TBL] [Abstract][Full Text] [Related]
16. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
Reddy BS; Hirose Y; Lubet R; Steele V; Kelloff G; Paulson S; Seibert K; Rao CV
Cancer Res; 2000 Jan; 60(2):293-7. PubMed ID: 10667579
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
[TBL] [Abstract][Full Text] [Related]
18. Suppression of intestinal polyposis by inhibition of COX-2 in Apc knockout mice.
Vane J
Jpn J Cancer Res; 1997 Nov; 88(11):inside front cover. PubMed ID: 9439674
[No Abstract] [Full Text] [Related]
19. Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator- activated receptor-gamma.
Shaik MS; Chatterjee A; Singh M
Clin Cancer Res; 2004 Feb; 10(4):1521-9. PubMed ID: 14977856
[TBL] [Abstract][Full Text] [Related]
20. Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis.
Takeda H; Sonoshita M; Oshima H; Sugihara K; Chulada PC; Langenbach R; Oshima M; Taketo MM
Cancer Res; 2003 Aug; 63(16):4872-7. PubMed ID: 12941808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
